Stock 300142 WALVAX BIOTECHNOLOGY CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Walvax Biotechnology Co., Ltd.

Equities

300142

CNE100000WN2

End-of-day quote Shenzhen S.E.
Other stock markets
 03:30:00 28/06/2024 am IST 		5-day change 1st Jan Change
11.38 CNY 0.00% Intraday chart for Walvax Biotechnology Co., Ltd. -0.87% -51.60%
26/06 Walvax Biotechnology Ends Vaccine Development Deal With Abogen Biotechnology MT
18/06 Walvax Terminates Coronavirus Vaccine Trials Due to Mutations MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Walvax Biotechnology Ends Vaccine Development Deal With Abogen Biotechnology
MT
Walvax Biotechnology Co., Ltd. Implements Final Cash Dividend for the Year 2023, Payable on 30 May 2024
CI
Walvax Biotechnology's Profit Drops 92%, Operating Income Slids 28% in Q1 2024
MT
Walvax Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
China's drugmakers can't sell mRNA shots but haven't quit yet
RE
Tranche Update on Walvax Biotechnology Co., Ltd.'s Equity Buyback Plan announced on April 5, 2023.
CI
Walvax Biotechnology Co., Ltd.'s Equity Buyback announced on April 5, 2023, has expired with 2,000,000 shares, representing 0.12% for CNY 72.2 million.
CI
Walvax Biotechnology's 2023 Profit Falls 42%
MT
Walvax Biotechnology Co., Ltd. Proposes Cash Profit Distribution for 2023
CI
Walvax Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Walvax Biotechnology Sees Up to 45% Drop in 2023 Profit
MT
Zhifei Biological Falls After Merck Secures Nod to Market HPV Vaccine in China
MT
Tranche Update on Walvax Biotechnology Co., Ltd.'s Equity Buyback Plan announced on April 5, 2023.
CI
Walvax Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Walvax Biotechnology's Unit Gets License to Market Pneumonia Vaccine in Indonesia; Shares Up 3%
MT
Tranche Update on Walvax Biotechnology Co., Ltd.'s Equity Buyback Plan announced on April 5, 2023.
CI
Walvax Biotechnology Unit Gets Nod to Carry Out Vaccine's Phase III Trial in Indonesia
MT
Walvax Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Tranche Update on Walvax Biotechnology Co., Ltd.'s Equity Buyback Plan announced on April 5, 2023.
CI
Walvax Biotechnology Chairman, Affiliates Complete Purchase of 101 Million Yuan Shares
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 300142 Stock
  4. News Walvax Biotechnology Co., Ltd.
  5. Highlights